Which Is a Better Investment, Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. Stock?
Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...
Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the “Artisan Mid Cap Value ...
Learn more about whether Syndax Pharmaceuticals, Inc. or Vericel Corporation is a better investment based on AAII's A+ ...
Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid ...
(Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) ...
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, in a deal that would expand the ...
Palm Valley Capital Management, an investment management firm, has issued the second-quarter 2026 investor letter for the ...
Travis Bazzana was drafted No. 1 overall. Cade Smith wasn't drafted at all. Parker Messick should have been drafted higher.
Palm Valley Capital Management, an investment management firm, has issued the second-quarter 2026 investor letter for the ...
Completion of enrollment anticipated within 12 months GALILEO-3 is intended to support the registration of FLT201 in ...
Major indexes declined Tuesday, pulled lower by chip stocks, after beginning the week with gains. The Dow Jones Industrial ...
Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results